TIPE2通过抑制TAK1激活缓解非酒精性脂肪性肝病
本研究探讨TIPE2在NAFLD中的作用。体外过表达或敲除TIPE2分别改善或加重肝细胞脂质蓄积和炎症;体内肝特异性Tipe2转基因小鼠代谢挑战后脂肪变、胰岛素抵抗、炎症和纤维化减轻,而敲除小鼠加重。机制上TIPE2结合TAK1,阻止TRAF6介导的TAK1泛素化,抑制TAK1-JNK/p38通路。
要点
- TIPE2过表达改善肝细胞脂质蓄积和炎症,敲除则加重。
- 肝特异性Tipe2转基因小鼠代谢挑战后NAFLD表型减轻,敲除小鼠加重。
- TIPE2通过结合TAK1并抑制其泛素化及下游JNK/p38激活来缓解NAFLD。
核心结论
- TIPE2通过阻断TAK1-JNK/p38通路抑制NAFLD进展,是有前景的NAFLD治疗靶点。
研究设计与样本
- 研究采用体外肝细胞过表达或敲除TIPE2结合代谢刺激,以及体内肝特异性Tipe2转基因和敲除小鼠模型。
- 通过RNA测序和机制实验探讨TIPE2的作用通路。
主要发现
- 体外过表达TIPE2显著改善肝细胞脂质蓄积和炎症,敲除则加重。
- 肝特异性Tipe2转基因小鼠代谢挑战后肝脏脂肪变、胰岛素抵抗、炎症和纤维化减轻,而敲除小鼠加重。
- RNA测序显示TIPE2与MAPK通路显著相关。
- TIPE2结合TAK1,阻止TRAF6介导的TAK1泛素化,抑制TAK1磷酸化及JNK/p38信号激活。
- 阻断TAK1活性可逆转肝特异性Tipe2敲除肝细胞和小鼠代谢刺激加重的肝脏代谢紊乱和炎症。
临床怎么用
- TIPE2及其下游TAK1-JNK/p38通路可作为NAFLD治疗的潜在靶点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: NAFLD prevalence has increased rapidly and become a major global health problem. Tumor necrosis factor α-induced protein 8-like 2 (TIPE2) plays a protective role in a cluster of liver diseases, such as autoimmune hepatitis, hepatitis B, and hepatocellular carcinoma. However, the function of TIPE2 in NAFLD remains unknown. Here, we investigated the role of TIPE2 in the development of NAFLD. APPROACH AND RESULTS: Our study found that in vitro overexpression or knockout of TIPE2 significantly ameliorated or aggravated lipid accumulation and inflammation in hepatocytes exposed to metabolic stimulation, respectively. Consistently, in vivo hepatic steatosis, insulin resistance, inflammation, and fibrosis were alleviated in hepatic Tipe2-transgenic mice but exaggerated in hepatic Tipe2-knockout mice treated by metabolic challenges. RNA sequencing revealed that TIPE2 was significantly associated with the mitogen-activated protein kinase pathway. Mechanistic experiments demonstrated that TIPE2 bound with transforming growth factor beta-activated kinase 1 (TAK1), prevented tumor necrosis factor receptor-associated factor 6-mediated TAK1 ubiquitination and subsequently inhibited the TAK1 phosphorylation and activation of TAK1-c-Jun N-terminal kinase (JNK)/p38 signaling. Further investigation showed that blocking the activity of TAK1 reversed the worsening of hepatic metabolic disorders and inflammation in hepatic-specific Tipe2-knockout hepatocytes and mice treated with metabolic stimulation. CONCLUSIONS: TIPE2 suppresses NAFLD advancement by blocking TAK1-JNK/p38 pathway and is a promising target molecule for NAFLD therapy.
引用
- Liu Y, Song J, Yang J, et al. Tumor Necrosis Factor α-Induced Protein 8-Like 2 Alleviates Nonalcoholic Fatty Liver Disease Through Suppressing Transforming Growth Factor Beta-Activated Kinase 1 Activation. Hepatology. 2021. PMID: 33768585. doi:10.1002/hep.31832
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。